Mr Seni Mylvaganam is a Consultant Oncoplastic Breast Surgeon, who specialises in the surgical assessment and management of breast symptoms and benign disease, breast cancer and breast reconstruction. He also has expertise in the practice of cosmetic breast surgery.
Seni initially qualified as a doctor in 2003, at the Royal Free and University College London Medical School, prior to which he completed his Bachelor's degree in Pharmacology at University College London. After completing his medical degree, he completed his specialist training with the National Oncoplastic Breast fellowship. The fellowship is restricted by competition to a select few breast and plastic surgeons each year. It is regarded as the gold standard for breast reconstructive training in the UK.
After completing his specialist registrar training, he was appointed as Consultant Oncoplastic Breast surgeon at the Royal Wolverhampton Hospitals NHS Trust. He also holds the role of professional clinical advisor in surgery to the NHS Breast screening programme. He is a member of the Association of Breast Surgery Clinical Practice and Standards Committee, part of the board who are responsible for UK national breast surgery practice standards.
Seni Mylvaganam - “I aim to provide every patient with the highest quality assessment, advice and treatment whether this is regarding benign breast symptoms, breast cancer care or cosmetic considerations. My patients are at the heart of this process and understanding their needs is essential to offering the best treatment tailored to each individual”.
MUMS offers 2 different gene tests.
Some specific rare gene defects can significantly increase your risk of developing breast cancer in your lifetime. 9 of the most common genes are looked for in this test which include BRCA 1 and BRCA 2.
This test identifies whether you have any one of these defects. If you have any of these gene defects your surgeon will then discuss with you what this means for your lifetime risk of breast cancer and how this should be managed.
This test is best used for women who have:
This test looks at your individual DNA for any specific variations (2803) that can be associated with breast cancer.
Based on any variations identified it then produces a score which gives you an individual risk of developing breast cancer in the next 10 years compared to the average woman of your age in the population.
This test is recommended for women between the ages of 30—75 of European origin.
This test cannot diagnose breast cancer only the risk of developing breast cancer.
Your risk score simply describes the chance that you might develop breast cancer and whether it is higher or lower than the general population.
Your score does not tell you whether your relatives are at increased risk. The risk score is also not something that can be passed onto children. Your children will have their own unique risk score from this test which is not related to your risk score.
This test is best used for women who:
This test does not specifically identify high risk gene changes for breast cancer such as BRCA 1 and BRCA 2. To specifically test for these genes MUMS offer a separate strong gene panel test (Invitae Breast Cancer STAT panel).
There are other risk factors such as lifestyle factors that can also increase your risk of breast cancer. Your breast surgeon will put together those risks to provide a bespoke guide to discuss with you.
The two tests offered do not give the same information and can be used together to give a personal risk for each woman. Your breast surgeon will guide you through which tests are recommended for you.